Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats
- PMID: 17541215
- DOI: 10.1291/hypres.30.359
Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats
Abstract
Azelnidipine is a new dihydropyridine calcium channel blocker that causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. In the present study, we examined the effects of oral or intravenous administration of azelnidipine on cardiovascular and renal sympathetic nerve activity (RSNA) responses to air-jet stress in conscious, unrestrained stroke-prone spontaneously hypertensive rats. Oral administration of high-dose azelnidipine (10 mg/kg per day) or nicardipine (150 mg/kg per day) for 10 days caused a significant and comparable decrease in blood pressure, but low-dose azelnidipine (3 mg/kg per day) did not. Air-jet stress increased mean arterial pressure (MAP), heart rate (HR) and RSNA. High-dose azelnidipine significantly attenuated the increases in MAP, HR and RSNA in response to air-jet stress while nicardipine did not. Low-dose azelnidipine significantly attenuated the pressor response with a trend of decrease in RSNA. Intravenous injection of azelnidipine induced a slowly developing depressor effect. To obtain a similar time course of decrease in MAP by azelnidipine, nicardipine was continuously infused at adjusted doses. Both drugs increased HR and RSNA significantly, while the change in RSNA was smaller in the azelnidipine group. In addition, intravenous administration of azelnidipine attenuated the responses of MAP, HR, and RSNA to air-jet stress; by comparison, the inhibitory actions of nicardipine were weak. In conclusion, oral or intravenous administration of azelnidipine inhibited cardiovascular and sympathetic responses to air-jet stress. This action of azelnidipine may be mediated at least in part by the inhibition of the sympathetic nervous system.
Similar articles
-
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.J Cardiovasc Pharmacol. 2008 Dec;52(6):555-60. doi: 10.1097/FJC.0b013e318192690e. J Cardiovasc Pharmacol. 2008. PMID: 19057394
-
Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.Hypertens Res. 2005 Dec;28(12):1017-23. doi: 10.1291/hypres.28.1017. Hypertens Res. 2005. PMID: 16671342
-
Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.Clin Exp Hypertens. 2007 Jan;29(1):13-21. doi: 10.1080/10641960601096745. Clin Exp Hypertens. 2007. PMID: 17190727
-
[Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].Nihon Yakurigaku Zasshi. 2003 Dec;122(6):539-47. doi: 10.1254/fpj.122.539. Nihon Yakurigaku Zasshi. 2003. PMID: 14639008 Review. Japanese.
-
Effect of calcium antagonists on sympathetic activity.Eur Heart J. 1998 Jun;19 Suppl F:F27-31. Eur Heart J. 1998. PMID: 9651732 Review.
Cited by
-
Effect of iron oxide nanoparticles on vascular function and nitric oxide production in acute stress-exposed rats.Physiol Res. 2020 Dec 22;69(6):1067-1083. doi: 10.33549/physiolres.934567. Epub 2020 Nov 2. Physiol Res. 2020. PMID: 33129250 Free PMC article.
-
Potential protective effects of Azelnidipine against cerebral ischemia-reperfusion injury in male rats.J Med Life. 2022 Nov;15(11):1384-1391. doi: 10.25122/jml-2022-0195. J Med Life. 2022. PMID: 36567842 Free PMC article.
-
Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis.High Blood Press Cardiovasc Prev. 2023 Sep;30(5):401-410. doi: 10.1007/s40292-023-00601-5. Epub 2023 Sep 28. High Blood Press Cardiovasc Prev. 2023. PMID: 37768510